Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 12.92% |
| 10 | Nu-Med Plus | 1.82 Mn | 1.82 Mn | - | 268.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19.55% |
| Sep 30, 2025 | 35.93% |
| Jun 30, 2025 | 32.52% |
| Mar 31, 2025 | 8.67% |
| Dec 31, 2024 | 81.35% |
| Sep 30, 2024 | -13.84% |
| Jun 30, 2024 | 28.92% |
| Mar 31, 2024 | 22.61% |
| Dec 31, 2023 | -232.84% |
| Sep 30, 2023 | 71.74% |
| Jun 30, 2023 | 58.12% |
| Mar 31, 2023 | 52.72% |
| Dec 31, 2022 | 101.95% |
| Sep 30, 2022 | 50.96% |
| Jun 30, 2022 | 76.06% |
| Mar 31, 2022 | 83.28% |
| Dec 31, 2021 | -330.45% |
| Sep 30, 2021 | 73.92% |
| Jun 30, 2021 | 73.30% |
| Mar 31, 2021 | -132.66% |